GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (NAS:OCGN) » Definitions » Net Margin %

Ocugen (Ocugen) Net Margin % : -157.27% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Ocugen Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Ocugen's Net Income for the three months ended in Dec. 2023 was $-9.49 Mil. Ocugen's Revenue for the three months ended in Dec. 2023 was $6.04 Mil. Therefore, Ocugen's net margin for the quarter that ended in Dec. 2023 was -157.27%.

The historical rank and industry rank for Ocugen's Net Margin % or its related term are showing as below:

OCGN' s Net Margin % Range Over the Past 10 Years
Min: -50748.84   Med: -3488.91   Max: -1045.03
Current: -1045.03


OCGN's Net Margin % is ranked worse than
73.44% of 1028 companies
in the Biotechnology industry
Industry Median: -159.44 vs OCGN: -1045.03

Ocugen Net Margin % Historical Data

The historical data trend for Ocugen's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Net Margin % Chart

Ocugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -50,748.84 - -3,488.91 -1,045.03

Ocugen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,100.96 - - - -157.27

Competitive Comparison of Ocugen's Net Margin %

For the Biotechnology subindustry, Ocugen's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocugen's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's Net Margin % distribution charts can be found below:

* The bar in red indicates where Ocugen's Net Margin % falls into.



Ocugen Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Ocugen's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-63.078/6.036
=-1,045.03 %

Ocugen's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-9.493/6.036
=-157.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocugen  (NAS:OCGN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Ocugen Net Margin % Related Terms

Thank you for viewing the detailed overview of Ocugen's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocugen (Ocugen) Business Description

Traded in Other Exchanges
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.
Executives
Junge Zhang director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Quan Anh Vu officer: CFO/CBO 22616 ERWIN STREET, WOODLAND HILLS CA 91367
Shankar Musunuri director, officer: Chief Executive Officer 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Arun Upadhyay officer: Chief Scientific Officer C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355
Ramesh Kumar director 375 PHEASANT RUN, NEWTOWN PA 18940
Kirsten Castillo director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Uday Kompella director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Prabhavathi Fernandes director 114 MILTON AVENUE, CHAPEL HILL NC 27514
Marna C Whittington director 2959 BARLEY MILL ROAD, YORKLYN DE 19736
Jessica Crespo officer: CAO/SVP, Finance C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355
Sanjay Subramanian officer: Chief Financial Officer 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Manish Potti director C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355
Vijay Tammara officer: Vice President 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Suha Taspolatoglu director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Kelly Beck officer: Vice President 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355